This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.2 | Special Copayment Reduction: V117 | Special Copayment Reduction period: 5 years |
| B. Synonyms | Multiple sulfatase deficiency, Austin Disease, mucopolysaccharidosis-sulfatidosis overlap syndrome, MSD |
| C. Adult onset | Likelihood of first onset in adulthood: low — Mostly presents in infancy or early childhood, and adult-onset presentation is very rare. |
| 1. History | First described by Austin in 1963; discovery of the SUMF1 gene in 2003 was a key milestone |
| 2. Causes | SUMF1 gene mutation → FGE deficiency → simultaneous loss of function of all cellular sulfatases |
| 3. Genetics | Autosomal recessive, SUMF1 (3p26.1); residual FGE activity inversely correlated with phenotypic severity |
| 4. Epidemiology | Ultra-rare, tens to hundreds of cases worldwide, incidence cannot be estimated |
| 5. Pathophysiology | FGE catalyzes the conversion of active-site cysteine → formylglycine in all sulfatases; deficiency causes accumulation of multiple substrates |
| 6. Symptoms | Combined phenotype of developmental regression, ichthyosis, signs of mucopolysaccharidosis, and neurodegeneration |
| 7. Signs | Hepatosplenomegaly, coarse facies, corneal clouding, white matter abnormalities on MRI, increased urinary GAG and sulfatides |
| 8. Screening | No established newborn screening; simultaneous measurement of multiple sulfatase activities when clinically suspected |
| 9. Diagnosis | Confirmation of reduced activity of at least 2 sulfatases + biallelic SUMF1 gene variants |
| 10. Treatment | No curative treatment, centered on symptomatic treatment; research on repurposing retinoid drugs under way |
| 11. Prognosis | Severe forms: death in infancy or childhood; mild forms may survive to adolescence but with progressive regression |
| 12. Prevention | Genetic counseling, carrier testing, PGT, prenatal diagnosis |
| 13. References | Austin J et al. Studies in metachromatic leukodystrophy XII and 9 other papers |
Multiple sulfatase deficiency (MSD) began to be recognized as a clinical entity in 1963, when the American neuroscientist James Austin reported an unusual case with features of both metachromatic leukodystrophy and mucopolysaccharidosis. Austin found that in this patient not only arylsulfatase A (ARSA) but multiple sulfatase enzyme activities were reduced simultaneously, and it was also named 'Austin disease'. Subsequent research revealed simultaneous deficiency of many sulfatases present in lysosomal and nonlysosomal compartments, including ARSA, arylsulfatase B (ARSB), arylsulfatase C (ARSC), iduronate-2-sulfatase (IDS), heparan N-sulfatase, and galactosamine-6-sulfatase.
In the 1990s and early 2000s, the hypothesis was put forward that a single mechanism explains this combined sulfatase deficiency, namely a defect in the post-translational modification process essential for sulfatase activity. In 2003, two research groups (Dierks et al. and Cosma et al.) simultaneously discovered the SUMF1 (sulfatase modifying factor 1) gene and showed that the formylglycine-generating enzyme (FGE) it encodes is a highly conserved modifying enzyme that activates all cellular sulfatases. This discovery became a historic milestone that clearly identified the molecular cause of MSD. Since then, structure-function studies of FGE, collection of pathogenic SUMF1 variants and genotype-phenotype correlation studies, and exploration of treatment strategies have been active.
The root cause of MSD is functional deficiency of the formylglycine-generating enzyme (FGE) due to pathogenic variants of the SUMF1 gene. FGE is an enzyme located in the endoplasmic reticulum that catalyzes the oxidative conversion of a specific cysteine residue in the active site of all cellular sulfatase enzymes to formylglycine (Cα-formylglycine, FGly). This post-translational modification is an absolute requirement for sulfatase enzymes to have the catalytic activity to hydrolyze their substrates, sulfate esters.
When structural instability or loss of function of FGE occurs due to SUMF1 gene variants, the activities of all types of sulfatases synthesized in the cell (including lysosomal and nonlysosomal sulfatases) are simultaneously deficient. This is the only example of a single-gene defect causing deficiency of multiple enzymes, a feature that fundamentally distinguishes MSD from simple single-enzyme deficiency diseases. The substrates of the deficient sulfatases—sulfated glycosaminoglycans (GAGs: heparan sulfate, dermatan sulfate, keratan sulfate, chondroitin sulfate), sulfatides, steroid sulfate esters, and others—accumulate together within lysosomes, producing a complex clinical phenotype.
MSD is inherited in an autosomal recessive manner. The causative gene, SUMF1, is located at chromosome 3p26.1 and consists of 9 exons. Dozens of pathogenic SUMF1 variants have been reported to date; missense variants are the most common, and nonsense variants, frameshift variants, splice site variants, and large deletions have also been reported.
According to genotype-phenotype correlation studies, the type of SUMF1 variant and the degree of residual FGE activity are strongly correlated with clinical severity. Nonsense variants or large deletions that produce no FGE protein at all result in the most severe phenotype, whereas missense variants in which FGE protein expression is maintained but only enzyme activity is reduced tend to be associated with mild or intermediate phenotypes. In other words, residual FGE enzyme activity is the main determinant of clinical severity. Clinical phenotypes may vary even among patients with the same genotype, suggesting the influence of genetic and environmental modifiers other than SUMF1.
MSD is one of the rarest lysosomal storage diseases known to date, with only tens to hundreds of cases reported worldwide. There are no accurate prevalence or incidence statistics, and the incidence is estimated at less than 1 per 1,000,000 births. No tendency to concentrate in particular races or regions has been reported, and it occurs sporadically in various ethnic groups worldwide.
One reason MSD is so rare is that FGE deficiency, which causes simultaneous deficiency of all sulfatases rather than a single enzyme deficiency, is functionally very disadvantageous and often results in severely nonviable phenotypes. The severe neonatal form causes hydrops fetalis, sometimes leading to stillbirth or death in the neonatal period, so the actual frequency may be much higher than reported. There are a few case reports in Asia, including Korea, but no systematic epidemiological survey data.
The pathogenic mechanism of MSD begins with functional FGE deficiency due to SUMF1 gene mutations. FGE is located in the lumen of the endoplasmic reticulum and catalyzes the conversion of the active-site cysteine to formylglycine as sulfatase precursor proteins are translated in the endoplasmic reticulum. Without this modification, sulfatases cannot catalyze binding to and hydrolysis of their substrate sulfate esters and become functionally inactive.
The sulfatases whose function is simultaneously lost due to FGE deficiency include arylsulfatase A (ARSA: sulfatide degradation), arylsulfatase B (ARSB: degradation of dermatan sulfate and chondroitin sulfate), arylsulfatase C (ARSC/STS: degradation of steroid sulfate esters), iduronate-2-sulfatase (IDS: degradation of heparan/dermatan sulfate), heparan N-sulfatase (SGSH), N-acetylgalactosamine-6-sulfatase (GALNS), galactose-6-sulfatase, glucosamine-6-sulfatase, and others. The combined accumulation of the substrates of these sulfatases produces a complex phenotype in which the features of individual diseases—metachromatic leukodystrophy (sulfatides), mucopolysaccharidosis type II (heparan sulfate), type IV (keratan sulfate), type VI (dermatan sulfate), and others—appear overlapping.
The clinical phenotype of MSD is characterized by overlapping symptoms of mucopolysaccharidosis and metachromatic leukodystrophy. Clinical forms are divided into neonatal, late infantile, and juvenile. The neonatal form is the most severe and may lead to death around birth due to hydrops fetalis. The late infantile form is the most common, with regression from normal development beginning within the first 1–2 years of life.
Typical clinical symptoms are ① developmental delay and regression (affecting motor, cognitive, and language development), ② ichthyosis (dry skin and scale-like keratinization), ③ coarse facies (mucopolysaccharidosis-like facial changes), ④ hepatosplenomegaly, ⑤ skeletal abnormalities (joint contractures, spinal curvature), and ⑥ neurological regression (seizures, spastic quadriplegia, ataxia). Ichthyosis is an important clinical clue for distinguishing MSD from other lysosomal storage diseases and is related to the accumulation of steroid sulfate esters in the skin due to deficiency of arylsulfatase C (the enzyme degrading steroid sulfate esters). Hearing impairment, decreased vision, corneal clouding, and cardiac valve abnormalities may also accompany it.
On physical examination, hepatosplenomegaly is found in almost all patients, and mucopolysaccharidosis-like coarse facies (flat nose, thick lips, broad forehead, gingival hypertrophy) are observed. On the skin, fine scale-like ichthyosis characteristically appears, widely distributed mainly on the limbs and trunk. Skeletal examination reveals joint contractures, brachydactyly of the hands and feet, lumbar kyphosis, and deformities of the thoracolumbar junction.
Ophthalmologic examination may show corneal clouding, and retinal abnormalities have also been reported. On neurological examination, a pattern of initial hypotonia gradually progressing to spasticity and hyperreflexia appears, and seizures commonly accompany it. Brain MRI shows T2 hyperintense lesions in the white matter of both cerebral hemispheres, reflecting myelin abnormalities due to sulfatide accumulation. Urinary glycosaminoglycan (GAG) measurement shows increased excretion of heparan sulfate and dermatan sulfate, and urinary sulfatide excretion is also increased. In blood and tissue samples, the activities of many sulfatases, such as ARSA, ARSB, and ARSC, are simultaneously reduced.
No country has currently established a systematic newborn screening program for MSD. This is because of the extremely low incidence of the disease and the fact that screening is not possible with single-enzyme activity measurement (because all sulfatases are simultaneously deficient, screening is not possible by measuring a specific single enzyme). Screening may become possible if multiplex enzyme assays that measure multiple enzyme activities simultaneously are developed, but for now diagnosis based on clinical suspicion is the standard.
Initial tests performed when MSD is clinically suspected include ① qualitative and quantitative analysis of urinary glycosaminoglycans (GAGs), ② urinary sulfatide analysis, and ③ simultaneous measurement of multiple sulfatase (ARSA, ARSB, ARSC, etc.) activities in leukocytes or skin fibroblasts. MSD should be strongly suspected when the activities of at least 2 of these sulfatases are reduced. In single-sulfatase deficiency diseases (MLD, Sanfilippo syndrome, Morquio syndrome, etc.), the remaining sulfatase activities are normal, so the finding of multiple reduced sulfatases is the key biochemical clue to MSD. Next-generation sequencing (NGS) of the SUMF1 gene is used for final confirmation.
The confirmatory criteria for MSD are ① biochemical confirmation that the activities of at least 2 sulfatases (lysosomal and/or nonlysosomal sulfatases) are simultaneously reduced to less than 10–30% of normal, or ② molecular genetic confirmation of pathogenic variants in both alleles of the SUMF1 gene. Enzyme activity is measured in peripheral blood leukocytes or cultured skin fibroblasts using fluorometric assays with fluorogenic substrates.
As a clinical diagnostic approach, MSD should be suspected in patients with features of both mucopolysaccharidosis and metachromatic leukodystrophy, especially when ichthyosis and developmental regression are present. White matter abnormalities on brain MRI, increased urinary GAG, and increased urinary sulfatides are findings suggestive of MSD. The differential diagnosis includes metachromatic leukodystrophy (MLD: isolated ARSA deficiency), each type of mucopolysaccharidosis (isolated enzyme deficiency), and other leukodystrophies. Histopathological examination shows various vacuole formations reflecting the accumulation of combined substrates within lysosomes. Prenatal diagnosis is possible by measuring sulfatase activities in CVS or amniotic cells and by SUMF1 gene analysis.
There is currently no curative treatment for MSD. In single-sulfatase deficiency diseases (e.g., MPS types I, II, VI), enzyme replacement therapy (ERT) is effective, but in MSD the number of deficient sulfatases is so large that supplementing all enzymes simultaneously is practically impossible. HSCT is effective in some lysosomal storage diseases, but experience in MSD is limited and sufficient efficacy is difficult to expect.
Symptomatic treatment is currently the core of standard treatment and includes ① neurological complications (seizures: anticonvulsants; spasticity: muscle relaxants, baclofen, etc.), ② skeletal abnormalities (orthopedic corrective surgery, physical therapy), ③ respiratory support (prevention of airway infections, mechanical ventilation support), ④ nutritional support (nasogastric tube, gastrostomy), ⑤ hearing and visual aids, and ⑥ ventriculoperitoneal shunting when hydrocephalus develops. In a recent drug repurposing study, screening of a library of 785 approved drugs found that the retinoid drugs tazarotene and bexarotene increase ARSA activity, and their therapeutic potential in MSD is being explored. In addition, restoring FGE through SUMF1 gene therapy could theoretically restore all sulfatase functions simultaneously, and this strategy is drawing attention as the most promising therapeutic approach.
The prognosis of MSD varies greatly with the degree of residual FGE activity and clinical form. In the severe neonatal form, death often occurs from hydrops fetalis or in the neonatal period. The late infantile form is the most common; neurological regression progresses over months to years, and most die in childhood. In the mild juvenile form, survival to adolescence is possible, but progressive neurological regression continues.
Because there is still no treatment that effectively modifies the course of disease in most MSD patients, focusing on maintaining quality of life and managing symptoms through supportive care is the realistic approach. Long-term prognostic data are very scarce because of the extremely low incidence of the disease. Multicenter registries and natural history studies need to be established, and improvement in prognosis is expected if the efficacy of gene therapy or drug repurposing therapies under development is confirmed.
Because MSD is an autosomal recessive genetic disease, when both parents are heterozygous carriers of pathogenic SUMF1 gene variants, there is a 25% chance of an affected child with each pregnancy. Genetic counseling is essential for couples with a family history or who have already had an affected child. Parental carrier testing is performed by SUMF1 gene analysis. In heterozygous carriers, sulfatase enzyme activity is about 50% of normal, but no clinical symptoms appear.
Prenatal diagnosis is possible by measuring multiple sulfatase enzyme activities or SUMF1 gene analysis in samples obtained by CVS at 10–12 weeks of gestation or amniocentesis at 16–18 weeks of gestation. Preimplantation genetic diagnosis (PGT) is a method of screening embryos for pathogenic SUMF1 variants after in vitro fertilization and transferring unaffected embryos, and can prevent the birth of a child with MSD. It is important to identify carriers early through cascade testing of the patient's family members (especially parents and siblings) and to provide genetic counseling on reproductive planning.